Company Encyclopedia
View More
name
Universe Pharmaceuticals
UPC.US
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sells of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements.
4.362 T
UPC.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking166/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-23.49%E
    • Profit Margin-49.87%E
    • Gross Margin34.57%C
  • Growth ScoreD
    • Revenue YoY-27.81%E
    • Net Profit YoY48.13%B
    • Total Assets YoY63.19%A
    • Net Assets YoY106.34%A
  • Cash ScoreE
    • Cash Flow Margin-200.51%D
    • OCF YoY-27.81%E
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreB
    • Gearing Ratio31.59%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More